Lung cancer
A cancer that starts in the lungs, usually in the cells that line the airways.1 Early on you may notice nothing; later it can cause a cough that will not go away, breathlessness or coughing up blood.2 You may be offered a combination of treatments, including surgery, chemotherapy, radiotherapy and targeted medicines. Which treatment you have depends on the type of lung cancer, how big it is and whether it has spread.3 Lung cancer is most often found in people aged 65 to 74. In about half of cases (51%), the cancer has already spread to a distant part of the body when it is found.4
Read more about Lung cancerTrial-stage treatments and research studies you can join
Filters
- Tests adding immunotherapy to chemotherapy after surgery for lung cancer
Tests pembrolizumab added to usual chemotherapy in adults with surgically removed non-small cell lung cancer.
Aberdeen, United StatesAlso Abilene, Adrian, ‘Aiea, Aitkin, Akron, Albuquerque, Alcoa, Alexandria, …Age 18+ - Testing lutetium Lu 177 dotatate against everolimus in lung neuroendocrine tumors
Compares radioactive lutetium Lu 177 dotatate with everolimus in adults with advanced lung neuroendocrine tumors.
Ankeny, United StatesAlso Aventura, Beverly Hills, Birmingham, Boston, Chicago, Cleveland, Columbus, Coral Gables, …Age 18+ - Tests zongertinib tablets in adults with advanced HER2-altered solid tumours
Tests zongertinib tablets in adults with advanced cancers that have HER2 gene changes.
Atlanta, United StatesAlso Beverly Hills, Birmingham, Cleveland, Dallas, Duarte, Durham, Fairfax, Fort Lauderdale, …Age 18+ - Tests BAY2927088 in adults with advanced lung cancer and EGFR or HER2 mutations
Tests BAY2927088 in adults with advanced non-small cell lung cancer with EGFR or HER2 mutations.
Atlanta, United StatesAlso Bethesda, Boston, Buffalo, Detroit, Duarte, Fairfax, Gilbert, Houston, …Age 18+ - Adding chemotherapy to immunotherapy for older adults with advanced lung cancer
Compares chemotherapy plus pembrolizumab with pembrolizumab alone in older adults with lung cancer.
Anaconda, United StatesAlso Ankeny, Antigo, Appleton, Ashland, Aurora, Aventura, Avon, Baltimore, …Age 70+ - Tests PLN-101095 with pembrolizumab in adults with advanced solid tumors
Tests PLN-101095, alone and with pembrolizumab, in adults with solid tumors that progressed on immunotherapy.
Atlanta, United StatesAlso Austin, East Brunswick, Edmonds, Fairfax, Fort Worth, Grand Rapids, Houston, Lake Success, …Age 18+ - Tests calderasib with pembrolizumab in lung cancer with KRAS G12C mutation
Tests calderasib plus pembrolizumab as first treatment in adults with KRAS G12C lung cancer.
Albany, United StatesAlso Bakersfield, Beverly Hills, Billings, Cincinnati, Houston, Kansas City, Kettering, Lancaster, …Age 18+ - Tests a cancer vaccine, OSE2101, against docetaxel in lung cancer
Tests the OSE2101 vaccine against docetaxel in lung cancer that stopped responding to immunotherapy.
Babylon, United StatesAlso Baltimore, Baton Rouge, Beverly Hills, Bonney Lake, Bradenton, Brandon, Brewster, Brooklyn, …Age 18+ - Durvalumab Versus Observation After Surgery for Early Lung Cancer With No Remaining Cancer Cells
Tests durvalumab after surgery in adults with early-stage non-small cell lung cancer.
Aberdeen, United StatesAlso ‘Aiea, Albuquerque, Allentown, Ames, Anaconda, Ankeny, Ann Arbor, Antigo, …Age 18+ - Tests sigvotatug vedotin with pembrolizumab in lung cancer with high PD-L1
Tests sigvotatug vedotin plus pembrolizumab in adults with advanced lung cancer and high PD-L1.
Avon, United StatesAlso Billings, Burnsville, Canton, Cleveland, Conroe, Coon Rapids, Edina, Elmhurst, …Age 18+ - Tests BAY 3713372 in adults with MTAP-deleted solid tumors
Tests a new drug, BAY 3713372, in adults with certain solid tumors lacking MTAP.
Aurora, United StatesAlso Birmingham, Boston, Denver, Duarte, Grand Rapids, Irving, Los Angeles, Milwaukee, …Age 18+ - Tests BL-M14D1 in adults with advanced lung and neuroendocrine cancers
Tests the drug BL-M14D1 in adults with advanced small cell lung cancer.
Atlanta, United StatesAlso Aurora, Columbus, Dallas, East Brunswick, Fairfax, Glendale, Greenville, Hackensack, …Age 18+ - Tests izalontamab brengitecan against chemotherapy in lung cancer after EGFR drug failure
Tests izalontamab brengitecan against platinum chemotherapy in adults with EGFR-mutated lung cancer.
Atlanta, United StatesAlso Boston, Charlottesville, Chattanooga, Chicago, Cleveland, Columbus, Edwards, Gainesville, …Age 18+ - Tests SAR445877 in lung cancer that stopped responding to immunotherapy
Tests SAR445877 in people with advanced lung cancer after prior immunotherapy.
Houston, United StatesAge 18+ - Tests calderasib with pembrolizumab as first treatment for KRAS G12C lung cancer
Tests calderasib and pembrolizumab together in adults with KRAS G12C-mutant advanced lung cancer.
Albany, United StatesAlso Bend, Beverly Hills, Birmingham, Farmington, Fort Lauderdale, Fredericksburg, Hackensack, Lafayette, …Age 18+ - Tests intismeran autogene with pembrolizumab and chemotherapy for advanced squamous lung cancer
Tests intismeran autogene with pembrolizumab and chemotherapy in adults with advanced squamous lung cancer.
Albany, United StatesAlso Ann Arbor, Austin, Cleveland, Corvallis, Fairfax, Nashville, Paramus, Seattle, …Age 18+ - Testing KST-6051 in advanced cancers with a KRAS mutation
Tests the safety of KST-6051 in adults with KRAS-mutant advanced solid tumors.
Boston, United StatesAlso Fairfax, Houston, Los Angeles, Philadelphia, Salt Lake City, San Antonio, Sarasota, TampaAge 18+ - Calderasib with durvalumab for KRAS G12C-mutant lung cancer after chemotherapy and radiation
Tests calderasib plus durvalumab in adults with KRAS G12C-mutant non-small cell lung cancer.
Albany, United StatesAlso Atlanta, Fairfax, Lincoln, Lisle, New Brunswick, Raleigh, SavannahAge 18+ - Compares BL-M14D1 plus atezolizumab with standard treatment in untreated small cell lung cancer
Tests BL-M14D1 with atezolizumab in adults with untreated extensive-stage lung cancer.
East Brunswick, United StatesAlso Fairfax, Glendale, Long Beach, Los Angeles, Miami, SpringdaleAge 18+ - Obrixtamig and ZL-1310 together for advanced small cell lung and other neuroendocrine cancers
Tests obrixtamig with ZL-1310 in adults with advanced small cell lung or neuroendocrine cancer.
Lexington, United StatesAlso Tampa, Washington D.C.Age 18+
Where treatment stands
On the EU list for lung cancer, tarlatamab, lurbinectedin, serplulimab and lazertinib got their first EU approval in 2025 or 2026.
Approved: 69
Officially approved for this disease in the EU, the US, Switzerland or France.
Human testing stage: 141
Being tested in people. Many treatments at this stage are never approved.
Animal testing stage: 3
Worked in animals in a study published in the last 12 months. Most treatments at this stage never reach people.
Lab research stage: 4
Worked on cells in the lab in a study published in the last 12 months. Most early ideas never reach people.
Placebo: a dummy treatment without the medicine, used for comparison.
Phase 1, 2, 3: the steps of testing in people. Phase 1 checks safety, phase 3 is the last step before approval.
The EU medicines agency (EMA) and its list of medicines in the EU, US prescribing labels (DailyMed, openFDA), the Swiss medicines register (Swissmedic), the French medicines database (ANSM) and the Health Canada drug database, checked on 11 November 2026. Every medicine links to its own official text.
A computer made this list from the official texts: it kept only medicines whose own approval text names the disease, wrote "Who it is for" from that text and checked it against the text a second time. People have not reviewed it yet.
The EU medicines agency (EMA), ClinicalTrials.gov and the EU trials register, checked on 10 November 2026. Every treatment links to its own records; the texts are written by AI from them.
Medicines approved only in single countries are not included. We did not check in which countries a medicine is sold or paid for. Phase 3 trials are listed from every country; only some phase 2 trials are listed, so 814 other open phase 2 trials are not listed.
Animal and lab research: studies listed in PubMed and published in the 12 months before 12 November 2026, found by a search for lung cancer. AI chose the treatments from the study summaries and wrote the texts; a second AI checked each one against its study summary. People have not reviewed them yet. Treatments already in the approved or human testing lists are left out. A result in animals or cells does not show that a treatment works in people.
Not medical advice. Talk to your doctor before you change any treatment.
The approval records under a medicine come from Drugs@FDA and the FDA labels (openFDA) and from the EU medicines agency’s medicine data, with its orphan designations, checked on 13 Nov 2026. A date is the medicine’s first approval, for any use; the quoted text is its approved use as written today.
Support organisations
Patient organisations and helplines in United States, for you and your family.
Lung cancer organisations in United States
- American Lung Association - Lung HelpLine
Free line staffed by nurses and respiratory therapists; Lung Health Navigators for people with lung cancer; screening assistance; interpretation in 250+ languages.
- National Cancer Institute – Cancer Information Service (CIS)
NCI's contact center: information specialists answer cancer questions from patients, families and the public by phone, chat and email.
- A Breath of Hope Lung Foundation
Minnesota-based foundation offering lung cancer patients and families support groups, transportation, education and peer companions, and funding research.
- ALK Positive
Patient-driven organization dedicated to improving the lives of ALK-positive (mostly lung) cancer patients worldwide.
- American Cancer Society
Nationwide US nonprofit helping people who face cancer: research, patient services, early detection, treatment information and education, with a cancer helpline on its site.
- Cactus Cancer Society
Young adult cancer resource and community: support programs for people diagnosed with cancer as young adults.
- Cancer Hope Network
Nonprofit providing free one-on-one support to cancer patients and families by matching them with trained volunteers who have had a similar experience.
- Cancer Nation
Survivor-led US cancer advocacy organization (formerly the National Coalition for Cancer Survivorship) working on quality cancer care and survivorship resources.
- EGFR Resisters
Grassroots, patient-driven community dedicated exclusively to EGFR-positive lung cancer.
- GO2 for Lung Cancer
HelpLine (Mon-Fri 9-5 ET), navigation to care, Phone Buddy peer support, Gathering HOPE online group, coping classes.
- Imerman Angels
Nonprofit offering free one-on-one cancer support and personalized mentoring that connects cancer fighters, survivors and caregivers with someone who has been there.
- KRAS Kickers
Lung cancer research advocacy community for patients with KRAS-mutated cancer.
- Lung Cancer Research Foundation
Foundation funding lung cancer research and providing free patient resources, including biomarker testing guides.
- LUNGevity Foundation
Lung cancer HELPLine (Mon-Fri 9-5 ET), navigation resources, peer mentoring, online communities, virtual meetups.
- Prevent Cancer Foundation
US foundation that helps people stay ahead of cancer through prevention and early detection; member of the Global Lung Cancer Coalition.
- The ROS1ders
Global group of patients and caregivers living with ROS1-positive cancer, bridging patients to research.
- Triage Cancer
National nonprofit providing free education on legal and practical issues (insurance, employment, finances) for people with cancer and caregivers.
General support in United States
- 988 Suicide & Crisis Lifeline
US national 24/7 free and confidential lifeline for anyone in suicidal crisis or emotional distress, reachable by calling or texting 988 or by chat.
- MedlinePlus
Free, easy-to-read health information service of the US National Library of Medicine (NIH) on diseases, conditions, drugs and wellness.
International organisations
Offer tissue or data
There are three ways to help research move faster.
Treatments approved outside the EU
Medicines for Lung cancer approved in the US or Japan that are not approved in the EU.
Checked on 11 Nov 2026 in the official lists of the US (FDA), Japan (PMDA, approvals since April 2004) and the EU (EMA). 8 uncertain matches are left out.
Your health insurer may pay part of the cost, sometimes all of it. This depends on your insurer, your plan and the country, so always ask your insurer before you go. For planned care in the EU, the EEA and Switzerland, ask about form S2.
“Miracle cure” fact checker
Social media spreads misinformation. Paste what you read here, and we'll tell you whether there is scientific evidence behind it.
What you paste is checked with AI (Anthropic, USA) and is not stored. Please leave out names and other personal details.
Before you pay for anything, ask three things
- Is there a published study in people?
- Can I have the full price in writing?
- What does my doctor say?
“Cures” others already fact-checked
- CBD (cannabidiol) & Lung cancer
- Vitamin C (incl. high-dose) & Lung cancer
- Ivermectin & Lung cancer
- Fenbendazole & Lung cancer
About Lung cancer
A cancer that starts in the lungs, usually in the cells that line the airways.1 Early on you may notice nothing; later it can cause a cough that will not go away, breathlessness or coughing up blood.2 You may be offered a combination of treatments, including surgery, chemotherapy, radiotherapy and targeted medicines. Which treatment you have depends on the type of lung cancer, how big it is and whether it has spread.3 Lung cancer is most often found in people aged 65 to 74. In about half of cases (51%), the cancer has already spread to a distant part of the body when it is found.4
What is it?
Lung cancer is cancer in one or both lungs.5 It usually starts in the cells that line the airways.1 There are two main types: non-small cell lung cancer, which is the more common one, and small cell lung cancer.1 They grow in different ways and are treated differently.1
It is one of the most common types of cancer.5 Lung cancer is most often found in people aged 65 to 74.4 Smoking is the most important risk factor for lung cancer.1 Second-hand smoke, radon gas in buildings, air pollution, asbestos at work and the lung disease COPD raise the risk too.6 Having a close relative who had lung cancer also makes it more likely.6
The first signs
You may not notice anything in the early stages.2 Sometimes it is found by chance on a chest X-ray done for another reason.7,1
- a cough that does not go away;2
- feeling short of breath;2
- coughing up blood;2
- pain in the chest or shoulder;2
- chest infections that keep coming back or do not get better;2
- losing weight without trying, a poor appetite or feeling tired all the time.2
Less common signs are easy to miss: a hoarse voice that does not go away, trouble swallowing, a swollen face or neck, or fingertips that change shape (clubbing).2 Some of these signs are very common and can be caused by other conditions.2
How doctors find out
If your family doctor thinks you could have lung cancer, they send you to a specialist.8 You will usually have a CT scan and a bronchoscopy: a thin, bendy tube with a small camera is passed into your lungs, and small samples can be taken.8,7
If you have lung cancer, you may need more tests, such as an MRI scan, a PET scan, a biopsy (a small piece of tissue checked under a microscope), blood tests and genetic testing.8,7 They show the type of cancer and how far it has spread, so your team can choose the right treatment.8 A specialist nurse is your main contact during and after treatment.8
Current treatment
Surgery, chemoradiation or targeted/immune drugs by stageSource: NCI
Will it get worse?
It depends on how big the cancer is, whether it has spread, and your general health.5 In about half of people (51%), the cancer has spread to a distant part of the body when it is found.4 Advanced lung cancer can be hard to treat.3 Then the aim is to slow the cancer down, and a palliative care team helps with symptoms and comfort.3 Lung cancer is the leading cause of cancer death in both men and women.1
Medicines: what helps, and what to watch for
Chemotherapy is medicine that kills cancer cells.3 It can be given before surgery to shrink a tumour, after surgery to lower the chance of the cancer coming back, or when surgery is not possible.3 Targeted medicines kill cancer cells or stop them growing as quickly. Your treatment can depend on whether the cancer has changes (mutations) in certain genes, such as EGFR or ALK.3,7 Immunotherapy helps your own immune system kill the cancer.3 Chemotherapy may be combined with other treatments, such as radiotherapy or immunotherapy.7,3
Good to know:
- Most people get some side effects of chemotherapy, but not all of them. Common ones are tiredness, feeling sick, a sore mouth, hair loss that is usually temporary, and numbness or tingling in the hands or feet;9
- Your team explains the benefits and side effects of each treatment and helps you manage them.3
Exercise and therapy help too
Breathlessness is hard to live with, but some things help.10
- practising slow, relaxed tummy breathing for 10 minutes, at least twice a day;10
- breathing in through your nose and out through narrowed lips;10
- a fan that blows cool air across your face;10
- pacing yourself and planning rest times;10
- small meals instead of a few big ones, and plenty to drink.10
Rest, but also some gentle physical activity, can help with tiredness.11 Many hospitals have clinics for breathing problems, or a physiotherapist or nurse who specialises in breathing.10
Surgery and radiotherapy, for some people
Surgery can remove the cancer from the lung.3 Depending on the tumour, the surgeon takes out a small piece, one lobe (section) of the lung, or the whole lung.7 Chemotherapy or radiotherapy may follow to kill any cancer cells left behind.7
Radiotherapy uses beams of radiation aimed at the tumour to kill cancer cells.3 It is used when surgery is not possible, after surgery, or when the cancer has spread.7,3 One type of radiotherapy uses special equipment to aim a larger than usual dose of radiation directly at the tumour once a day for several days.7
Is there a cure?
For most people, not yet: today's treatments do not cure most lung cancers.1 Cancer found early, for example through screening, may be easier to treat.5,2 Clinical trials are taking place for people with all stages of non-small cell lung cancer.7
Median survival
About 17 months with two immunotherapy medicines, once it has spread (non-small cell lung cancer)Source: NCI PDQ, 2025
Measured in: First-line treatment of stage IV or recurrent non-small cell lung cancer without EGFR or ALK changes: the CheckMate 227 trial (1,739 patients)
The figures behind it
NCI PDQ (health professional, non-small cell lung cancer), CheckMate 227 (1,739 patients, first-line, stage IV or recurrent NSCLC without EGFR or ALK changes): median overall survival 17.1 months with nivolumab plus ipilimumab vs 14.9 months with chemotherapy when PD-L1 was at least 1% (1,189 patients), and 17.4 vs 12.2 months when PD-L1 was below 1% (550 patients). Small cell lung cancer was not part of this figure.
Sources
Written in plain words by Frontlight from these pages:
- MedlinePlus: Lung Cancer
- NHS: Lung cancer – Symptoms
- NHS: Lung cancer – Treatment
- NCI SEER: Cancer Stat Facts: Lung and Bronchus Cancer
- NHS: Lung cancer – What is lung cancer?
- NHS: Lung cancer – Causes
- NCI PDQ: Non-Small Cell Lung Cancer Treatment (PDQ) – Patient Version
- NHS: Lung cancer – Tests and next steps
- NHS: Chemotherapy – Side effects
- Cancer Research UK (charity): Lung cancer – Coping with breathlessness
- Cancer Research UK (charity): Lung cancer – Coping and support